The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Transgenic murine models. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Transgenic murine models is a key innovation area in pharmaceuticals

Transgenic murine models refer to mice that have been genetically altered for the purposes of understanding the in vivo functions of genes. The gene to be studied is injected into the nucleus of a fertilised mouse egg, and becomes integrated into the genome. Transgenic murine models help researchers better understand debilitating diseases such as cancer, Alzheimer’s diseases, Parkinson’s disease, diabetes, and more.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 290+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of transgenic murine models.

Key players in transgenic murine models – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to transgenic murine models

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Regeneron Pharmaceuticals 3924 Unlock Company Profile
Sanofi 481 Unlock Company Profile
F. Hoffmann-La Roche 384 Unlock Company Profile
Biocytogen Pharmaceuticals (Beijing) 224 Unlock Company Profile
Omeros 118 Unlock Company Profile
Children's Medical Center 116 Unlock Company Profile
Ligand Pharmaceuticals 102 Unlock Company Profile
Jackson ImmunoResearch Laboratories 91 Unlock Company Profile
Amgen 89 Unlock Company Profile
Centre National de la Recherche Scientifique 84 Unlock Company Profile
AbCellera Biologics 83 Unlock Company Profile
Deerfield Management 78 Unlock Company Profile
Takeda Pharmaceutical 76 Unlock Company Profile
C. H. Boehringer Sohn 73 Unlock Company Profile
Bristol-Myers Squibb 72 Unlock Company Profile
E. Merck 72 Unlock Company Profile
Erasmus MC 68 Unlock Company Profile
Biogen 66 Unlock Company Profile
Crescendo Biologics 61 Unlock Company Profile
Merus 60 Unlock Company Profile
Japan Science and Technology Agency 53 Unlock Company Profile
Kirin Holdings 49 Unlock Company Profile
Homology Medicines 47 Unlock Company Profile
Sangamo Therapeutics 46 Unlock Company Profile
Encoded Therapeutics 44 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 44 Unlock Company Profile
Pfizer 41 Unlock Company Profile
AstraZeneca 40 Unlock Company Profile
Helmholtz Association of German Research Centres 39 Unlock Company Profile
CSL 39 Unlock Company Profile
Massachusetts General Hospital 38 Unlock Company Profile
Transposagen Biopharmaceuticals 38 Unlock Company Profile
General Hospital 36 Unlock Company Profile
Taiga Biotechnologies 35 Unlock Company Profile
Samsung Life Public Welfare Foundation 34 Unlock Company Profile
BASF 34 Unlock Company Profile
Vivoryon Therapeutics 34 Unlock Company Profile
Academia Sinica 33 Unlock Company Profile
St. Jude Children’s Research Hospital 33 Unlock Company Profile
PhoenixBio 33 Unlock Company Profile
Shiseido 32 Unlock Company Profile
Eli Lilly and 31 Unlock Company Profile
City of Hope 31 Unlock Company Profile
OncoTherapy Science 31 Unlock Company Profile
ImmunoGen 30 Unlock Company Profile
Merck & Co 29 Unlock Company Profile
TransGenic 28 Unlock Company Profile
United Therapeutics 28 Unlock Company Profile
APEIRON Biologics 28 Unlock Company Profile
Fred Hutchinson Cancer Research Center 27 Unlock Company Profile

Source: GlobalData Patent Analytics

Regeneron Pharmaceuticals is the leading patent filer in transgenic murine models. Regeneron Pharmaceuticals has a market cap of $78.64bn and is primarily focused on cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases. Regeneron has created its VelociSuite technology platform, which includes VelociGene, VelociMouse, VelocImmune and VelociMab. Together, these technologies increase the efficiency and decrease the time involved in the discovery and generation of drug candidates. The company’s VelociMouse technology enables the immediate generation of genetically altered mice directly from modified embryonic stem cells. In 2022, AbCellera entered into a collaboration with Regeneron for four discovery programmes based on AbCellera’s antibody discovery engine and Regeneron’s VelocImmune mice. Sanofi and F. Hoffmann-La Roche are the other key patent filers in transgenic murine models.

In terms of application diversity, Shattuck Labs is the top company, followed by Lunan Pharmaceutical Group and Candel Therapeutics. By means of geographic reach, Arrowhead Pharmaceuticals holds the top position. Ozgene and Ligand Pharmaceuticals stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.